Latest News

Eight-year phase 3 ADAURA trial data show adjuvant osimertinib boosts survival in patients with resected EGFR-mutant NSCLC.

Pharmacists play a key role in guiding age- and risk-based vaccination decisions to protect against invasive and noninvasive disease.

As pharmaceutical markets become increasingly dynamic, health systems may benefit from shifting toward unit-level economic frameworks that evaluate cost and margin performance.

September highlights Blood Cancer Awareness Month, focusing on education, early diagnosis, and support for multiple myeloma, lymphoma, and leukemia patients.

Machine-learning and multiple-imputation models could help researchers estimate missing baseline Eastern Cooperative Oncology Group performance status in advanced prostate cancer.

Gepotidacin and zoliflodacin show comparable efficacy to standard care for urogenital gonorrhea, offering promising alternatives given the recent rise in antimicrobial resistance.

At the 2026 New England Institute of Ambulatory Care Pharmacists (NEIAP) Annual Forum, Jennifer Goldman detailed how monitoring data drive engagement—and how a new dual sensor readies pharmacists for ketone alerts.

Phase 3 HARMONi-2 interim analysis shows first bispecific PD-1/VEGF antibody outperforming standard immunotherapy in first-line NSCLC.

Apitegromab-mstn is cleared as an add-on to SMN2-targeted treatment for patients aged 2 and older, directly addressing muscle loss.

Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.

The expanded approval of leniolisib makes it the first approved treatment for pediatric patients with activated phosphoinositide 3-kinase delta syndrome.

Carole R. Berini, PhD, and Saamir Pasha, MPH, of Ontada discuss a model designed to estimate missing baseline ECOG performance status in advanced prostate cancer and the validation needed before it can support broader real-world evidence research.

Contraceptive access gaps driven by federal rollbacks, provider shortages, and stalled state legislation could be narrowed by letting trained pharmacists prescribe birth control independently.

Cancer diagnoses among civilians exposed to 9/11 dust keep rising, with strained health programs struggling to meet growing needs.

Long-term use of PPIs—and, to a lesser degree, histamine 2 receptor antagonists—may increase the risk of bacterial infections, including C difficile and pneumonia, underscoring the need for pragmatic prescribing.

With childhood immunization rates sliding and outbreaks accelerating, pharmacist-led counseling and vaccine administration can boost vaccination rates.

Once-daily oral deucrictibant extended-release significantly reduced hereditary angioedema attacks compared with placebo in the pivotal phase 3 CHAPTER-3 trial.

A Danish registry study found that COVID-19 infection was linked to a lower, not higher, risk of subsequent type 1 diabetes (T1D) in unvaccinated individuals younger than 30 years.

A high-dose vaccine cut hospitalizations for flu, pneumonia, and cardiorespiratory disease in older adults with asthma, COPD, and other chronic lung conditions.

The data support GPRC5D-directed CAR T-cell therapy as a potential option following prior BCMA-targeted treatment.

Investing in formalized technician education not only supports competency development but also strengthens workforce stability.